Best Practice & Research Clinical Haematology
Volume 19, Issue 4 , Pages 757-767 , December 2006

Immunomodulation in myelodysplastic syndromes

  • Mikkael A. Sekeres, MD, MS (Assistant Professor of Medicine)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 216 445 9353; Fax: +1 216 444 9464.
  • Alan List, MD (Professor of Oncology and Medicine, Chief, Malignant Hematology Division, and H. Lee Moffitt Cancer Center & Research Institute Professor of Medicine)

REFERENCES 

  1. List AF, Vardiman J, Issa JP, DeWitte TM. Myelodysplastic syndromes. Hematology (American Society of Hematology Education Program). 2004;297–317
  2. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO. 1999;10(12):1419–1432
  3. Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. British Journal of Haematology. 1992;82(2):358–367
  4. Williamson PJ, Kruger AR, Reynolds PJ, Hamblin TJ, Oscier DG. Establishing the incidence of myelodysplastic syndrome. British Journal of Haematology. 1994;87(4):743–745
  5. Paul B, Reid MM, Davison EV, Abela M, Hamilton PJ. Familial myelodysplasia: progressive disease associated with emergency of monosomy 7. British Journal of Haematology. 1987;65(3):321–323
  6. Pasqualetti P, Casale R, Colantonio D, Collacciani A. Occupational risk for hematological malignancies. American Journal of Hematology. 1991;38(2):147–149
  7. Karp JE, Smith MA. The molecular pathogenesis of treatment-induced (secondary) leukemias: foundations for treatment and prevention. Seminars in Oncology. 1997;24(1):103–113
  8. Allampallam K, Shetty V, Mundle S, Dutt D, Kravitz H, Reddy PL, et al. Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. International Journal of Hematology. 2002;75(3):289–297
  9. Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood. 2001;97(5):1427–1434
  10. Kitagawa M, Saito I, Kuwata T, Yoshida S, Yamaguchi S, Takahashi M, et al. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1997;11(12):2049–2054
  11. Schipperus M, Sonneveld P, Lindemans J, Hagemeijer A, Vink N, Pegels J, et al. The effects of interleukin-3, GM-CSF, and G-CSF on the growth kinetics of colony-forming cells in myelodysplastic syndromes. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1990;4(4):267–272
  12. Sugimoto K, Hirano N, Toyoshima H, Chiba S, Mano H, Takaku F, et al. Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Blood. 1993;81(11):3022–3026
  13. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology. 1982;51(2):189–199
  14. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292–2302
  15. Haase D, Steidl C, Schanz J, Schabla R, Pfeilstöcker M, Nösslinger T, et al. Correlation of Cytogenetic Findings with Morphology, Clinical Course and Prognosis in 2124 Patients with MDS. Blood. 2005;106:232a
  16. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–2088
  17. Malcovati L, Germing U, Kuendgen A, Porta MD, Invernizzi R, Giagounidis A, et al. A WHO Classification-Based Prognostic Scoring System (WPSS) for Predicting Survival in Myelodysplastic Syndromes. Blood. 2005;106:232a
  18. Hellstrom-Lindberg E, Negrin R, Stein R, Krantz S, Lindberg G, Vardiman J, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. British Journal of Haematology. 1997;99(2):344–351
  19. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin+granulocyte colony-stimulating factor: significant effects on quality of life. British Journal of Haematology. 2003;120(6):1037–1046
  20. Corral LG, Kaplan G. Immunomodulation by thalidomide and thalidomide analogues. Annals of the Rheumatic Diseases. 1999;58(supplement 1):I107–I113
  21. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98(1):210–216
  22. Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology. 1996;31(2–3):213–221
  23. Parman T, Wiley MJ, Wells PG. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nature Medicine. 1999;5(5):582–585
  24. Raza A, Meyer P, Dutt D, Zorat F, Lisak L, Nascimben F, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood. 2001;98(4):958–965
  25. Cheson BD, Bennett JM, Kantarjian H, Schiffer CA, Nimer SD, Lowenberg B, et al. Myelodysplastic syndromes standardized response criteria: further definition. Blood. 2001;98(6):1985
  26. Musto P, Falcone A, Sanpaolo G, Bisceglia M, Matera R, Carella AM, et al. Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes. Haematologica. 2002;87(8):884–886
  27. Strupp C, Germing U, Aivado M, Misgeld E, Haas R, Gattermann N. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2002;16(1):1–6
  28. Morena-Aspitia A, Geyer S, Li C-Y, et al. N998B: multicenter phase II trial of thalidomide (thal) in adult patients with myelodysplastic syndromes (MDS). Blood. 2002;100:96a
  29. List A, Tate W, Glinsmann-Gibson B. The immunomodulatory thalidomide analog, CC-5013, inhibits tropic response in VEGF in AML cells by abolishing cytokine-induced PI3/Akt activation. Blood. 2002;100:139a
  30. List A, Kurtin S, Roe D, Buresh A, Mahadevan D, Fuchs D, et al. Efficacy of Lenalidomide in Myelodysplastic Syndromes. The New England Journal of Medicine. 2005;352:
  31. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96(12):3671–3674
  32. Buesche G, Dieck S, Giagounidis A, Bock O, Wilkens L, Schlegelberger B, et al. Anti-angiogenic in vivo effect of lenalidomide (CC-5013) in myelodysplastic syndrome with del(5q) chromosome abnormality and its relation to the course of disease. Blood. 2005;106:113a
  33. List A, Dewald G, Bennett J, Giagounadis A, Raza A, Feldman E, et al. Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: Results of the multicenter MDS-003 study. Journal of Clinical Oncology (Proceedings of the American Society of Clinical Oncology). 2005;23:2s
  34. Raza A, Candoni A, Khan U, Lisak L, Tahir S, Silvestri F, et al. Remicade as TNF suppressor in patients with myelodysplastic syndromes. Leukemia & Lymphoma. 2004;45(10):2099–2104
  35. Salituro FG, Germann UA, Wilson KP, Bemis GW, Fox T, Su MS. Inhibitors of p38 MAP kinase: therapeutic intervention in cytokine-mediated diseases. Current Medicinal Chemistry. 1999;6(9):807–823
  36. Saarni MI, Linman JW. Preleukemia. The hematologic syndrome preceding acute leukemia. The American Journal of Medicine. 1973;55(1):38–48

PII: S1521-6926(06)00038-7

doi: 10.1016/j.beha.2006.06.001

Best Practice & Research Clinical Haematology
Volume 19, Issue 4 , Pages 757-767 , December 2006

Article Tools